CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Versus Selinexor-Dexamethasone for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Title:
CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Versus Selinexor-Dexamethasone for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Author:
Moreau, P. Usmani, S.Z. van de Donk, N.W.C.J. Garfall, A.L. Delforge, M. Oriol, A. Nooka, A. Rosiñol, L. Bahlis, N. RodrÃguez Otero, P. Martin, T. Diels, J. Van Sanden, S. Pei, L. Ammann, E. Chastain, K. Marshall, A. Slavcev, M. Londhe, A. Krishnan, A.